MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Hepatitis - HCV' source. Wed, 08 Feb 2012 18:15:38 +0100 http://www.medworm.com/index.php?rid=5526312&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Resistance%2FExpert%2520Viewpoints%2FExpert_Viewpoint_1.aspx Learning Module - Christoph Sarrazin, MD, reviews highlights on resistance to direct-acting antiviral agents from the 2011 American Association for the Study of Liver Diseases conference. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5526312 Mon, 19 Dec 2011 15:55:56 +0100 5526312 http://www.medworm.com/index.php?rid=5506169&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FPoordad_NEJM_2011%2FCapsule.aspx Capsule Summary - The addition of boceprevir significantly improved SVR rates in both blacks and nonblacks and among patients poorly responsive to interferon. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506169 Thu, 15 Dec 2011 09:25:58 +0100 5506169 http://www.medworm.com/index.php?rid=5506171&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FFoster_Gastroenterology_2011%2FSlideset.aspx CCO Slideset - Among genotype 2 patients, SVR rates significantly higher with triple therapy vs telaprevir monotherapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506171 Thu, 15 Dec 2011 00:00:00 +0100 5506171 http://www.medworm.com/index.php?rid=5506170&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FPoordad_NEJM_2011%2FSlideset.aspx CCO Slideset - The addition of boceprevir significantly improved SVR rates in both blacks and nonblacks and among patients poorly responsive to interferon. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506170 Thu, 15 Dec 2011 00:00:00 +0100 5506170 http://www.medworm.com/index.php?rid=5516083&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FUsing%2520HCV%2520PIs%2FModules%2FCase%2520Vignettes.aspx Learning Module - Join Graham R. Foster, FRCP, PhD; Paul Y. Kwo, MD; and Fred Poordad, MD, as they discuss optimal management strategies for 8 case scenarios of patients considering or receiving treatment with boceprevir or telaprevir. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5516083 Wed, 14 Dec 2011 12:10:27 +0100 5516083 http://www.medworm.com/index.php?rid=5506172&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FFoster_Gastroenterology_2011%2FCapsule.aspx Capsule Summary - Among genotype 2 patients, SVR rates significantly higher with triple therapy vs telaprevir monotherapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506172 Wed, 14 Dec 2011 09:42:38 +0100 5506172 http://www.medworm.com/index.php?rid=5506173&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FBacon_NEJM_2011%2FSlideset.aspx CCO Slideset - High SVR rates with triple therapy in several difficult-to-treat populations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506173 Wed, 14 Dec 2011 00:00:00 +0100 5506173 http://www.medworm.com/index.php?rid=5506178&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FZeuzem_NEJM_2011%2FSlideset.aspx CCO Slideset - Among patients who had previously failed HCV therapy, achievement of SVR with telaprevir-based therapy was greatest for those with previous relapse and poorest for those with previous null response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506178 Tue, 13 Dec 2011 00:00:00 +0100 5506178 http://www.medworm.com/index.php?rid=5506177&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FBacon_NEJM_2011%2FCapsule.aspx Capsule Summary - High SVR rates with triple therapy in several difficult-to-treat populations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506177 Tue, 13 Dec 2011 00:00:00 +0100 5506177 http://www.medworm.com/index.php?rid=5506176&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FGarg_Hepatology_2011%2FSlideset.aspx CCO Slideset - Findings suggest that changes in cyclosporine and tacrolimus pharmacokinetics during coadministration with telaprevir could lead to serious or life-threatening adverse events, particularly in HCV-infected patients with compromised hepatic function. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506176 Tue, 13 Dec 2011 00:00:00 +0100 5506176 http://www.medworm.com/index.php?rid=5506175&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FJacobson_NEJM_2011%2FSlideset.aspx CCO Slideset - Among treatment-naive genotype 1 HCV–infected patients, telaprevir administration significantly improved SVR rates over pegIFN/RBV alone, and allowed for 24-week therapy in almost 60% of patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506175 Tue, 13 Dec 2011 00:00:00 +0100 5506175 http://www.medworm.com/index.php?rid=5506174&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FSherman_NEJM_2011%2FSlideset.aspx CCO Slideset - Majority of patients receiving telaprevir-based triple therapy achieved eRVR and were randomized to 24 vs 48 weeks of peginterferon and ribavirin. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5506174 Tue, 13 Dec 2011 00:00:00 +0100 5506174 http://www.medworm.com/index.php?rid=5495576&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FJacobson_NEJM_2011%2FCapsule.aspx Capsule Summary - Among treatment-naive genotype 1 HCV–infected patients, telaprevir administration significantly improved SVR rates over pegIFN/RBV alone, and allowed for 24-week therapy in almost 60% of patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5495576 Mon, 12 Dec 2011 00:00:00 +0100 5495576 http://www.medworm.com/index.php?rid=5495575&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FZeuzem_NEJM_2011%2FCapsule.aspx Capsule Summary - Among patients who had previously failed HCV therapy, achievement of SVR with telaprevir-based therapy was greatest for those with previous relapse and poorest for those with previous null response. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5495575 Mon, 12 Dec 2011 00:00:00 +0100 5495575 http://www.medworm.com/index.php?rid=5495574&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FSherman_NEJM_2011%2FCapsule.aspx Capsule Summary - Majority of patients receiving telaprevir-based triple therapy achieved eRVR and were randomized to 24 vs 48 weeks of peginterferon and ribavirin. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5495574 Mon, 12 Dec 2011 00:00:00 +0100 5495574 http://www.medworm.com/index.php?rid=5495573&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2011%2520JO%2520Hepatitis%2520Volume%25205%2FArticles%2FGarg_Hepatology_2011%2FCapsule.aspx Capsule Summary - Findings suggest that changes in cyclosporine and tacrolimus pharmacokinetics during coadministration with telaprevir could lead to serious or life-threatening adverse events, particularly in HCV-infected patients with compromised hepatic function. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5495573 Mon, 12 Dec 2011 00:00:00 +0100 5495573 http://www.medworm.com/index.php?rid=5469865&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Assays%2FInteractive%2520Virtual%2520Presentation%2FHCV_Assays_Slides.aspx CCO Slideset - In this Downloadable Slideset, Paul Y. Kwo, MD, provides practical recommendations regarding the use of the various HCV assays available to guide the management of patients considering or already receiving treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5469865 Fri, 02 Dec 2011 00:00:00 +0100 5469865 http://www.medworm.com/index.php?rid=5458985&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Assays%2FInteractive%2520Virtual%2520Presentation%2FiVP.aspx Resource - In this Interactive Virtual Presentation, Paul Y. Kwo, MD, provides practical recommendations regarding the use of the various HCV assays available to guide the management of patients considering or already receiving treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5458985 Tue, 29 Nov 2011 10:44:54 +0100 5458985 http://www.medworm.com/index.php?rid=5409717&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FFuture%2520HCV%2520Drugs%2FCCO%2520Slideset%2FSlides.aspx CCO Slideset - Review the current benefits and limitations with protease inhibitor-based HCV therapies, and the emerging data on potential future regimens and the advances they represent. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5409717 Tue, 15 Nov 2011 00:00:00 +0100 5409717 http://www.medworm.com/index.php?rid=5388954&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FUsing%2520HCV%2520PIs%2FCCO%2520Slideset%2FUsing_HCV_PIs_Slides.aspx CCO Slideset - Review the approved indications and proper management of HCV-infected patients with the newly approved protease inhibitors. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5388954 Tue, 08 Nov 2011 00:00:00 +0100 5388954 http://www.medworm.com/index.php?rid=5337354&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Resistance%2FModule%2FExpert_Roundtable.aspx Learning Module - Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5337354 Mon, 17 Oct 2011 14:37:26 +0100 5337354 http://www.medworm.com/index.php?rid=5227310&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520New%2520Agents%2FSlideset%2520Module%2FSlides_Downloadable.aspx CCO Slideset - In this downloadable slideset, a panel of HCV experts outline the optimal use of boceprevir and telaprevir in the treatment of hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5227310 Thu, 15 Sep 2011 00:00:00 +0100 5227310 http://www.medworm.com/index.php?rid=5227309&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Update%2520for%2520NPs%2520and%2520PAs%2FInteractive%2520Virtual%2520Presentation%2FHCV_Update_for_NPs_PAs_Slides.aspx CCO Slideset - In this downloadable slideset, Elizabeth Britton, MSN, reviews the key elements of HCV management for NPs and PAs. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5227309 Thu, 15 Sep 2011 00:00:00 +0100 5227309 http://www.medworm.com/index.php?rid=5227308&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520New%2520Agents%2FSlideset%2520Module%2FSlides_Module.aspx Learning Module - World-renowned HCV experts provide guidance on the use of boceprevir and telaprevir in the treatment of chronic hepatitis C. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5227308 Thu, 15 Sep 2011 00:00:00 +0100 5227308 http://www.medworm.com/index.php?rid=5227311&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FOn-treatment_Slides_German.aspx CCO Slideset - In diesem herunterladbaren Foliensatz liefert Graham R. Foster, FRCP, PhD, einen Fall-basierten Überblick über die optimalen Strategien zur Handhabung von Patienten, die für chronische Hepatitis C behandelt werden, einschließlich einer Beurteilung der wichtigsten Entscheidungspunkte während einer auf Proteasehemmern basierenden Behandlung. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5227311 Wed, 14 Sep 2011 00:00:00 +0100 5227311 http://www.medworm.com/index.php?rid=5185002&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FAdverse%2520Events_Slides.aspx CCO Slideset - In this downloadable slideset, Mitchell L. Shiffman, MD, outlines practical strategies that clinicians can implement to improve outcomes among their patients receiving treatment for chronic hepatitis C, with a focus on the new challenges arising during treatment with HCV protease inhibitor–based regimens. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5185002 Fri, 02 Sep 2011 00:00:00 +0100 5185002 http://www.medworm.com/index.php?rid=5185003&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Update%2520for%2520NPs%2520and%2520PAs%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - Elizabeth Britton, MSN, reviews the key elements of care for physician assistants and nurse practitioners caring for hepatitis C patients, including the use of newly approved protease inhibitors for treatment of patients infected with HCV genotype 1. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5185003 Thu, 01 Sep 2011 14:47:50 +0100 5185003 http://www.medworm.com/index.php?rid=5176202&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FAdverse%2520Events.aspx Resource - In this Interactive Virtual Presentation, Mitchell L. Shiffman, MD, provides a case-based overview of practical strategies that clinicians can implement to improve outcomes among their patients receiving treatment for chronic hepatitis C, with a focus on the new challenges arising during treatment with HCV protease inhibitor–based regimens. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5176202 Mon, 29 Aug 2011 11:21:02 +0100 5176202 http://www.medworm.com/index.php?rid=5163559&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline_Slides_German.aspx CCO Slideset - In diesem herunterladbaren Foliensatz bespricht Peter Ferenci, MD, die Belastung durch HCV, Empfehlungen und Herausforderungen im Zusammen mit HCV-Screening, Strategien zur Beratung von Patienten bezüglich der Eignung für eine Behandlung; die wichtigsten Baseline-Prädiktoren für das Ansprechen auf eine HCV-Therapie und den potenziellen Einfluss von neu zugelassenen Therapien auf die Behandlung von HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5163559 Wed, 24 Aug 2011 00:00:00 +0100 5163559 http://www.medworm.com/index.php?rid=5163560&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline_Slides_Spanish.aspx CCO Slideset - En este conjunto de diapositivas descargable, el Dr. Peter Ferenci revisa la carga del VHC, las recomendaciones y los retos relativos a la detección del VHC, las estrategias para el consejo sobre aquellos tratamientos para los que son candidatos los pacientes, predictores clave en el momento inicial de la respuesta al tratamiento contra el VHC, y el posible impacto de las terapias recientemente autorizadas sobre el tratamiento del VHC. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5163560 Mon, 22 Aug 2011 12:00:00 +0100 5163560 http://www.medworm.com/index.php?rid=5163561&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline_Slides_French.aspx CCO Slideset - Dans cet ensemble de diapositives téléchargeable, Peter Fercinci, MD, analyse le fardeau du VHC, les recommandations et les défis se rapportant au dépistage du VHC, aux stratégies pour conseiller les patients candidats au traitement, les prédicteurs de réponse au traitement anti-VHC clés de référence, et l'impact potentiel de traitements nouvellement approuvés pour la prise en charge du VHC. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5163561 Mon, 22 Aug 2011 00:00:00 +0100 5163561 http://www.medworm.com/index.php?rid=5110629&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520New%2520Agents%2FModule%2FPractical_Guide.aspx Learning Module - With the advice of a panel of experts, this practical guide has been prepared as a consensus recommendation for how telaprevir and boceprevir should be used in the treatment of patients with HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5110629 Mon, 08 Aug 2011 11:30:24 +0100 5110629 http://www.medworm.com/index.php?rid=5098755&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FOn-treatment_Slides.aspx CCO Slideset - In this downloadable slideset, Graham R. Foster, FRCP, PhD, provides a case-based review of optimal strategies for on-treatment management of patients undergoing therapy for chronic hepatitis C, including an assessment of key decision points during protease inhibitor–based therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5098755 Wed, 03 Aug 2011 00:00:00 +0100 5098755 http://www.medworm.com/index.php?rid=5070712&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHIV%2FAnnual%2520Updates%2F2011%2520Annual%2520Update%2FModules%2FDAA%2520Naive.aspx Learning Module - Mark S. Sulkowski, MD, reviews the latest data on and the approved indications of telaprevir and boceprevir in treatment-naive, genotype 1 HCV–infected patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5070712 Wed, 27 Jul 2011 09:42:47 +0100 5070712 http://www.medworm.com/index.php?rid=5070713&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FOn-treatment.aspx Resource - In this Interactive Virtual Presentation, Graham R. Foster, FRCP, PhD, provides a case-based review of optimal strategies for on-treatment management of patients undergoing therapy for chronic hepatitis C, including an assessment of key decision points during protease inhibitor–based therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5070713 Mon, 25 Jul 2011 17:13:31 +0100 5070713 http://www.medworm.com/index.php?rid=5089186&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline_slides.aspx CCO Slideset - In this downloadable slideset, Peter Ferenci, MD, reviews the burden of HCV, recommendations and challenges related to HCV screening, strategies for counseling patients on treatment candidacy, key baseline predictors of response to HCV therapy, and the potential impact of newly approved therapies on HCV management. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5089186 Thu, 14 Jul 2011 00:00:00 +0100 5089186 http://www.medworm.com/index.php?rid=5031378&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FBattling%2520HCV%2FInteractive%2520Virtual%2520Presentations%2FBaseline_slides.aspx CCO Slideset - In this downloadable slideset, Peter Ferenci, MD, reviews the burden of HCV, recommendations and challenges related to HCV screening, strategies for counseling patients on treatment candidacy, key baseline predictors of response to HCV therapy, and the potential impact of newly approved therapies on HCV management. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=5031378 Thu, 14 Jul 2011 00:00:00 +0100 5031378 http://www.medworm.com/index.php?rid=4755380&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FCorrections%2FInteractive%2520Virtual%2520Presentation%2FOpportune_Time_Slides.aspx CCO Slideset - David Paar, MD, and David A. Wohl, MD, discuss the complexities of providing care for HIV and HCV moninfected and coinfected patients within correctional settings. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4755380 Tue, 26 Apr 2011 00:00:00 +0100 4755380 http://www.medworm.com/index.php?rid=4726656&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FCorrections%2FInteractive%2520Virtual%2520Presentation%2FOpportune_Time.aspx Resource - David Paar, MD, and David A. Wohl, MD, discuss the intricacies of testing and managing patients with HIV and/or hepatitis C virus in the setting of corrections institutions. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4726656 Fri, 15 Apr 2011 10:54:22 +0100 4726656 http://www.medworm.com/index.php?rid=4699154&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FCapsules%2F1360.aspx Capsule Summary - Patients receiving pegIFN alfa-2a more than twice as likely to experience myalgia, pyrexia, arthralgia, chills, and rash; pegIFN lambda associated with lower incidence of hematologic toxicity but higher incidence of bilirubin elevations and (at the highest dose) AST/ALT elevations relative to pegIFN alfa-2a. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4699154 Fri, 08 Apr 2011 16:53:25 +0100 4699154 http://www.medworm.com/index.php?rid=4699155&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FCapsules%2F1359.aspx Capsule Summary - The safety profile of mericitabine plus pegIFN/RBV was similar to that of pegIFN/RBV alone, and there was no evidence of mericitabine resistance variants at baseline, during treatment, or in patients with relapse by Week 36. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4699155 Fri, 08 Apr 2011 13:35:57 +0100 4699155 http://www.medworm.com/index.php?rid=4699156&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FCapsules%2F5.aspx Capsule Summary - The inclusion of a 4-week pegIFN/RBV lead-in phase before telaprevir-based therapy had no impact on virologic response or relapse rates. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4699156 Fri, 08 Apr 2011 10:09:43 +0100 4699156 http://www.medworm.com/index.php?rid=4694057&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F1356.aspx Capsule Summary - Study results are first to indicate that some previous null responders may achieve SVR with a combination of 2 direct-acting antivirals without pegIFN/RBV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694057 Thu, 07 Apr 2011 10:52:49 +0100 4694057 http://www.medworm.com/index.php?rid=4694058&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F12.aspx Capsule Summary - Virologic response to 4-week pegIFN/RBV lead-in was a stronger predictor of SVR than IL28B genotype or any other single baseline factor. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694058 Thu, 07 Apr 2011 10:42:42 +0100 4694058 http://www.medworm.com/index.php?rid=4694059&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F62.aspx Capsule Summary - Virologic response rates were lower and resistance-associated virologic breakthrough rates were higher among patients infected with genotype 1a vs 1b HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694059 Wed, 06 Apr 2011 16:34:27 +0100 4694059 http://www.medworm.com/index.php?rid=4694060&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F60.aspx Capsule Summary - Among patients with extended rapid virologic response to BI 201335 240 mg plus pegIFN/RBV, SVR rates were similar with 24 vs 48 total weeks of pegIFN/RBV therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694060 Tue, 05 Apr 2011 16:15:06 +0100 4694060 http://www.medworm.com/index.php?rid=4694061&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F13.aspx Capsule Summary - Within patient subgroups defined by previous response to pegIFN/RBV therapy, SVR rates were higher with telaprevir-based therapy vs pegIFN/RBV retreatment and did not vary markedly by IL28B genotype. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694061 Tue, 05 Apr 2011 16:11:26 +0100 4694061 http://www.medworm.com/index.php?rid=4694062&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F1363.aspx Capsule Summary - Although dual therapy with VX-222 plus telaprevir was associated with unacceptably high rates of virologic breakthrough requiring termination of dual-therapy treatment arms, the combination of VX-222/telaprevir plus pegIFN/RBV was associated with robust antiviral efficacy, including no cases of virologic breakthrough, in this Week 12 interim analysis. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694062 Mon, 04 Apr 2011 16:56:47 +0100 4694062 http://www.medworm.com/index.php?rid=4843534&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FBerlin%25202011%2FTracks%2FFrom%2520Podium%2520to%2520Practice%2FCapsules%2F9.aspx Capsule Summary - Patients infected with genotype 1a HCV had numerically higher rate of failure to achieve SVR and higher frequency of resistance-associated variants vs patients with genotype 1b in this resistance surveillance study of the SPRINT-2 and RESPOND-2 phase III trials. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4843534 Sun, 03 Apr 2011 16:26:08 +0100 4843534 http://www.medworm.com/index.php?rid=4694063&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F9.aspx Capsule Summary - Patients infected with genotype 1a HCV had numerically higher rate of failure to achieve SVR and higher frequency of resistance-associated variants vs patients with genotype 1b in this resistance surveillance study of the SPRINT-2 and RESPOND-2 phase III trials. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694063 Sun, 03 Apr 2011 16:26:08 +0100 4694063 http://www.medworm.com/index.php?rid=4694064&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F7.aspx Capsule Summary - SVR rates numerically lower in patients with advanced fibrosis/cirrhosis who received response-guided boceprevir plus pegIFN/RBV therapy vs 48 weeks of boceprevir plus pegIFN/RBV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694064 Sun, 03 Apr 2011 16:02:24 +0100 4694064 http://www.medworm.com/index.php?rid=4694065&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F1376.aspx Capsule Summary - Among patients treated with TMC435-containing regimens, mean HCV RNA reductions were similar across IL28B genotypes through 24 weeks. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694065 Sun, 03 Apr 2011 15:38:45 +0100 4694065 http://www.medworm.com/index.php?rid=4694066&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F6.aspx Capsule Summary - More than one half of previous partial responders and relapsers who had a < 1 log10 reduction in HCV RNA following a lead-in phase nevertheless went on to achieve SVR following telaprevir-based therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694066 Sun, 03 Apr 2011 13:26:07 +0100 4694066 http://www.medworm.com/index.php?rid=4694067&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F8.aspx Capsule Summary - According to population sequencing, 60% of patients no longer had detectable resistant variants within 16 months of treatment failure following telaprevir-based therapy in phase III clinical trials; loss of detectable resistance was more rapid among patients infected with genotype 1b vs 1a HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694067 Fri, 01 Apr 2011 15:59:07 +0100 4694067 http://www.medworm.com/index.php?rid=4694068&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F4.aspx Capsule Summary - The addition of alisporivir to pegIFN/RBV therapy was generally well tolerated but was associated with higher rates of hyperbilirubinemia vs pegIFN/RBV alone; cases of hyperbilirubinemia resolved early during treatment and were not associated with evidence of hepatotoxicity. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694068 Fri, 01 Apr 2011 13:19:39 +0100 4694068 http://www.medworm.com/index.php?rid=4694069&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FBerlin+2011%2FTracks%2FFrom+Podium+to+Practice%2FCapsules%2F1370.aspx Capsule Summary - In this 14-day proof-of-concept study, no adverse pharmacokinetic interactions were observed between PSI-938 and PSI-7977, and no patient experienced virologic breakthrough with either drug as monotherapy or with both agents in combination. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694069 Fri, 01 Apr 2011 11:11:42 +0100 4694069 http://www.medworm.com/index.php?rid=4694070&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FMoucari_Gut_2010%2FSlideset.aspx CCO Slideset - Statistically significant correlation observed among HOMA-IR value and HCV RNA level. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694070 Mon, 14 Mar 2011 00:00:00 +0100 4694070 http://www.medworm.com/index.php?rid=4694072&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal+Options%2FCollections%2F2010+JO+Hepatitis+Volume+4%2FArticles%2FMarcellin_Gastroenterol_2010%2FSlideset.aspx CCO Slideset - Nearly all patients (96%) assigned to 24 total weeks of therapy based on undetectable HCV RNA from Weeks 4-20 achieved SVR. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694072 Fri, 04 Mar 2011 16:59:41 +0100 4694072 http://www.medworm.com/index.php?rid=4694073&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FFuture+Generations%2FInteractive+Virtual+Presentation%2FFuture+Generations.aspx CCO Slideset - Stefan Zeuzem, MD, describes the development of new classes of drugs for treatment of patients with hepatitis C infection and reviews parameters that will govern the use of these drugs. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4694073 Tue, 01 Mar 2011 16:43:08 +0100 4694073 http://www.medworm.com/index.php?rid=4518656&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FMarcellin_Gastroenterol_2010%2FCapsule.aspx Capsule Summary - Nearly all patients (96%) assigned to 24 total weeks of therapy based on undetectable HCV RNA from Weeks 4-20 achieved SVR. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4518656 Thu, 24 Feb 2011 12:58:41 +0100 4518656 http://www.medworm.com/index.php?rid=4518657&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FFuture%2520Generations%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - Stefan Zeuzem, MD, reviews the characteristics of directly acting antivirals currently in development and discusses the role these agents may have in future combination regimens for HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4518657 Thu, 24 Feb 2011 09:30:51 +0100 4518657 http://www.medworm.com/index.php?rid=4350523&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Pharmacists%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - In this Interactive Virtual Presentation, Betty J. Dong, PharmD, FASHP, FCCP, AAHIVE, and Megan R. Mahoney, MD, review how pharmacists can play a key role in addressing current HCV management challenges and those that may arise with the approval of newer agents. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4350523 Fri, 14 Jan 2011 14:16:46 +0100 4350523 http://www.medworm.com/index.php?rid=4350524&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Pharmacists%2FInteractive%2520Virtual%2520Presentation%2FHCV_Pharmacists_Slides.aspx CCO Slideset - In this Downloadable Slideset, a pharmacist and physician team review how pharmacists can play a key role during all aspects of HCV management. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4350524 Fri, 14 Jan 2011 00:00:00 +0100 4350524 http://www.medworm.com/index.php?rid=4339444&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FHCV_Treatment.aspx Learning Module - Nezam H. Afdhal, MD, FRCPI; Jean-Michel Pawlotsky, MD, PhD; and Stefan Zeuzem, MD, discuss key clinical trial findings relating to new HCV therapies and treatment strategies from the 2010 AASLD meeting. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4339444 Wed, 12 Jan 2011 11:30:39 +0100 4339444 http://www.medworm.com/index.php?rid=4332855&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Pharmacists%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - In this Interactive Virtual Presentation, Betty J. Dong, PharmD, FASHP, FCCP, AAHIVE, and Megan R. Mahoney, MD, review how pharmacists can play a key role during all aspects of HCV management. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4332855 Sun, 09 Jan 2011 00:00:00 +0100 4332855 http://www.medworm.com/index.php?rid=4226864&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520HCV%2520Therapies%2FInteractive%2520Virtual%2520Presentation%2FIVP_Slides.aspx CCO Slideset - In this Downloadable Slideset, expert faculty members provide an overview of key management strategies for new HCV agents in frontline and treatment-experienced settings. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4226864 Fri, 03 Dec 2010 00:00:00 +0100 4226864 http://www.medworm.com/index.php?rid=4215824&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520HCV%2520Therapies%2FInteractive%2520Virtual%2520Presentation%2FIVP.aspx Resource - In this Interactive Virtual Presentation, expert faculty members provide an overview of key management strategies for new HCV agents in frontline and treatment-experienced settings. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4215824 Tue, 30 Nov 2010 11:02:20 +0100 4215824 http://www.medworm.com/index.php?rid=4169180&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB5.aspx Capsule Summary - The safety profile of TMC435 plus pegIFN/RBV was similar to placebo plus pegIFN/RBV with < 10% of patients in each treatment arm discontinuing therapy because of adverse events. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4169180 Mon, 15 Nov 2010 00:00:00 +0100 4169180 http://www.medworm.com/index.php?rid=4156454&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FThompson-Gastroenterol-2010%2FSlideset.aspx CCO Slideset - The odds of reducing RBV dose due to anemia is 47% lower in patients with ITPA variants than in patients without ITPA polymorphisms. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4156454 Thu, 11 Nov 2010 00:00:00 +0100 4156454 http://www.medworm.com/index.php?rid=4156453&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FSulkowski_Gastroenterology_2010%2FSlideset.aspx CCO Slideset - Fewer treatment discontinuations observed among patients without anemia and those with anemia when using ESAs vs patients with anemia not using ESAs. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4156453 Thu, 11 Nov 2010 00:00:00 +0100 4156453 http://www.medworm.com/index.php?rid=4153053&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FHarrison_Hepatology_2010%2FSlideset.aspx CCO Slideset - Fewer treatment discontinuations among patients with baseline elevated LDL or low HDL and statin users. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4153053 Wed, 10 Nov 2010 00:00:00 +0100 4153053 http://www.medworm.com/index.php?rid=4153052&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FKwo-Hepatology-2010%2FSlideset.aspx CCO Slideset - Potential for treatment duration to be modified according to HCV RNA decline in first 4 weeks of treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4153052 Wed, 10 Nov 2010 00:00:00 +0100 4153052 http://www.medworm.com/index.php?rid=4145682&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB1.aspx Capsule Summary - The addition of ribavirin or ribavirin plus pegIFN was associated with increased HCV RNA responses during 4 weeks of GS-9256 plus tegobuvir therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4145682 Tue, 09 Nov 2010 09:33:55 +0100 4145682 http://www.medworm.com/index.php?rid=4136072&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F216.aspx Capsule Summary - Sustained virologic response rates were similar with response-guided vs 48-week boceprevir plus pegIFN/RBV therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4136072 Wed, 03 Nov 2010 17:30:45 +0100 4136072 http://www.medworm.com/index.php?rid=4136073&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F211.aspx Capsule Summary - Addition of telaprevir to pegIFN/RBV increased eligibility for short-duration therapy with high rates of SVR in treatment-naive patients with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4136073 Wed, 03 Nov 2010 16:39:56 +0100 4136073 http://www.medworm.com/index.php?rid=4128017&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB4.aspx Capsule Summary - Treatment with boceprevir plus pegIFN/RBV for 24 weeks equally effective as 44 weeks in treatment-naive patients with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128017 Wed, 03 Nov 2010 11:47:04 +0100 4128017 http://www.medworm.com/index.php?rid=4128018&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F32.aspx Capsule Summary - The highest danoprevir dosing arm was terminated based on the incidence of grade 4 ALT elevations; ritonavir-boosted danoprevir will move forward into next phase of development. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128018 Tue, 02 Nov 2010 19:43:12 +0100 4128018 http://www.medworm.com/index.php?rid=4128019&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB8.aspx Capsule Summary - Viral breakthrough occurred in 55% of patients receiving BMS-790052 plus BMS-650032 through Week 12; however, no cases of viral breakthrough occurred among patients receiving BMS-790052 and BMS-650032 in combination with pegIFN/RBV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128019 Tue, 02 Nov 2010 17:25:52 +0100 4128019 http://www.medworm.com/index.php?rid=4128020&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2FLB2.aspx Capsule Summary - PegIFN/RBV for 24 and 48 weeks after 12 weeks of telaprevir associated with high rates of SVR in difficult-to-treat populations of patients with genotype 1 HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128020 Tue, 02 Nov 2010 16:27:32 +0100 4128020 http://www.medworm.com/index.php?rid=4128021&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F828.aspx Capsule Summary - Increased HCV RNA response with combination telaprevir plus pegIFN/RBV therapy relative to telaprevir monotherapy or pegIFN/RBV alone was suggestive of a potential synergistic effect between telaprevir and pegIFN/RBV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128021 Tue, 02 Nov 2010 12:14:09 +0100 4128021 http://www.medworm.com/index.php?rid=4128022&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F81.aspx Capsule Summary - RG7128 not associated with treatment-emergent viral breakthrough or resistance. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128022 Mon, 01 Nov 2010 19:35:46 +0100 4128022 http://www.medworm.com/index.php?rid=4128023&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F31.aspx Capsule Summary - ANA598 200 mg BID in combination with pegIFN/RBV demonstrated similar safety and tolerability vs pegIFN/RBV alone; however, ANA598 400 mg BID plus pegIFN/RBV was associated with a higher incidence of rash. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128023 Mon, 01 Nov 2010 19:33:12 +0100 4128023 http://www.medworm.com/index.php?rid=4128024&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F82.aspx Capsule Summary - Vaniprevir plus pegIFN/RBV significantly increased RVR rates compared with pegIFN/RBV alone in treatment-naive patients with chronic HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128024 Mon, 01 Nov 2010 18:14:17 +0100 4128024 http://www.medworm.com/index.php?rid=4128025&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F821.aspx Capsule Summary - Virologic response rates to pegIFNlambda/RBV were numerically higher in patients with IL-28B CC vs non-CC genotype. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128025 Mon, 01 Nov 2010 17:40:08 +0100 4128025 http://www.medworm.com/index.php?rid=4128026&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F807.aspx Capsule Summary - MK-5172 well tolerated with no serious adverse events or treatment discontinuations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128026 Mon, 01 Nov 2010 16:04:36 +0100 4128026 http://www.medworm.com/index.php?rid=4128027&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FAASLD%25202010%2FTracks%2FHCV%2520Treatment%2FCapsules%2F810.aspx Capsule Summary - An IL-28B C/C genotype imbalance of 10% to 20% was predicted to result in 0.2-1.0 log10 IU/mL differences in Week 4 mean HCV RNA reduction between treatment arms in early-phase trials. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128027 Mon, 01 Nov 2010 11:50:39 +0100 4128027 http://www.medworm.com/index.php?rid=4128028&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FNew%2520HCV%2520Therapies%2FCCO%2520Slideset%2FNew%2520HCV%2520Therapies%2520Slides.aspx CCO Slideset - Review the latest data on novel targeted anti-HCV agents and gain a better understanding into the potential changes forthcoming in hepatitis C treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4128028 Mon, 01 Nov 2010 00:00:00 +0100 4128028 http://www.medworm.com/index.php?rid=4120654&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FThompson-Gastroenterol-2010%2FCapsule.aspx Capsule Summary - The odds of reducing RBV dose due to anemia is 47% lower in patients with ,ITPA variants than in patients without ITPA polymorphisms. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4120654 Fri, 29 Oct 2010 00:00:00 +0100 4120654 http://www.medworm.com/index.php?rid=4120653&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FReijnders_Hepatology_2010%2FCapsule.aspx Capsule Summary - The results of a small single-center study demonstrated that nearly all patients with HBeAg seroconversion who discontinued nucleos(t)ide analogue therapy after at least 6 months of consolidation had HBV disease progression within 5 years. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4120653 Fri, 29 Oct 2010 00:00:00 +0100 4120653 http://www.medworm.com/index.php?rid=4101995&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FHarrison_Hepatology_2010%2FCapsule.aspx Capsule Summary - Fewer treatment discontinuations among patients with baseline elevated LDL or low HDL and statin users. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4101995 Mon, 25 Oct 2010 00:00:00 +0100 4101995 http://www.medworm.com/index.php?rid=4101994&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FKwo-Hepatology-2010%2FCapsule.aspx Capsule Summary - Potential for treatment duration to be modified according to HCV RNA decline in first 4 weeks of treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4101994 Mon, 25 Oct 2010 00:00:00 +0100 4101994 http://www.medworm.com/index.php?rid=4101993&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FSulkowski_Gastroenterology_2010%2FCapsule.aspx Capsule Summary - Fewer treatment discontinuations observed among patients without anemia and those with anemia when using erythropoiesis-stimulating agents vs patients with anemia not using erythropoiesis-stimulating agents. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4101993 Mon, 25 Oct 2010 00:00:00 +0100 4101993 http://www.medworm.com/index.php?rid=3860029&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FFerenci_Gastroenterology_2010%2FSlideset.aspx CCO Slideset - SVR rates comparable between groups due to higher rate of voluntary treatment cessation after Week 48 in patients randomized to 72 weeks of treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3860029 Thu, 12 Aug 2010 00:00:00 +0100 3860029 http://www.medworm.com/index.php?rid=3814429&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FHonda_Gastroenterol_2010%2FSlideset.aspx CCO Slideset - Treatment nonresponse strongly associated with upregulation of interferon-stimulated genes before treatment initiation. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3814429 Tue, 03 Aug 2010 16:23:41 +0100 3814429 http://www.medworm.com/index.php?rid=3814431&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FMcHutchison-NEJM-2010%2FSlideset.aspx CCO Slideset - High SVR rates observed in both previous relapsers and nonresponders, although rates higher in previous relapsers. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3814431 Tue, 03 Aug 2010 00:00:00 +0100 3814431 http://www.medworm.com/index.php?rid=3814430&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FHonda_Gastroenterol_2010%2FCapsule.aspx Capsule Summary - Treatment nonresponse strongly associated with upregulation of interferon-stimulated genes prior to treatment initiation. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3814430 Tue, 03 Aug 2010 00:00:00 +0100 3814430 http://www.medworm.com/index.php?rid=3803952&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FJournal%2520Options%2FCollections%2F2010%2520JO%2520Hepatitis%2520Volume%25204%2FArticles%2FMcHutchison-NEJM-2010%2FCapsule.aspx Capsule Summary - High SVR rates observed in both previous relapsers and nonresponders, although rates higher in previous relapsers. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3803952 Fri, 30 Jul 2010 00:00:00 +0100 3803952 http://www.medworm.com/index.php?rid=3664029&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FHCV.aspx Learning Module - Paul Y. Kwo, MD; Jean-Michel Pawlotsky, MD, PhD; and Stefan Zeuzem, MD, review key data presented at the 2010 EASL meeting on emerging agents and new treatment strategies for patients infected with hepatitis C virus. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3664029 Mon, 14 Jun 2010 13:49:46 +0100 3664029 http://www.medworm.com/index.php?rid=4083340&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHIV%2FResources%2FCME%2520Options%2FCME%2520Options%2520TEST%2520Segment%2520VP%2FInteractive%2520Virtual%2520Presentation%2FHCV_Core.aspx Resource - Michael P. Manns, MD; Peter Ferenci, MD; and David R. Nelson, MD, review the efficacy and safety profiles of approved and late-phase interferons as well as the role of interferons in the emerging area of targeted antiviral agents. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=4083340 Mon, 07 Jun 2010 18:35:19 +0100 4083340 http://www.medworm.com/index.php?rid=3638038&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Interferons%2FInteractive%2520Virtual%2520Presentation%2FHCV_Core_Slides.aspx CCO Slideset - Peter Ferenci, MD; Michael P. Manns, MD; and David R. Nelson, MD; discuss the safety and efficacy of approved and investigational interferons and their potential future role with direct-acting antivirals. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3638038 Mon, 07 Jun 2010 00:00:00 +0100 3638038 http://www.medworm.com/index.php?rid=3601158&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FHCV%2520Interferons%2FInteractive%2520Virtual%2520Presentation%2FHCV_Core.aspx Resource - Michael P. Manns, MD; Peter Ferenci, MD; and David R. Nelson, MD, review the efficacy and safety profiles of approved and late-phase interferons as well as the role of interferons in the emerging area of targeted antiviral agents. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3601158 Mon, 24 May 2010 14:09:23 +0100 3601158 http://www.medworm.com/index.php?rid=3893327&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FStay%2520Tuned%25201%2FVolume%25201%2520Edition%25201%2FActivity%2FApril%2520Module%2FEdition%25201%2520Video.aspx Resource - Nezam H. Afdhal, MD, FRCPI; Steven Flamm, MD; and Fred Poordad, MD, review the clinical implications of the latest diagnostic, prognostic, and treatment data pertaining to patients infected with hepatitis C virus. In this edition of Stay Tuned Hepatitis, Nezam H. Afdhal, MD, FRCPI, provides insight into the clinical utility of new prognostic and diagnostic tools for hepatitis C; Steven Flamm, MD, reviews strategies for managing mild liver disease in the setting of HCV in 2010; and Fred Poordad, MD, highlights the likely impact of new HCV therapies on current practices in the clinic. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3893327 Thu, 06 May 2010 17:00:38 +0100 3893327 http://www.medworm.com/index.php?rid=3540033&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FStay%2520Tuned%25201%2FVolume%25201%2520Edition%25201%2FActivity%2FApril%2520Module%2FEdition%25201%2520Video.aspx Resource - Nezam H. Afdhal, MD, FRCPI; Steven Flamm, MD; and Fred Poordad, MD, review the clinical implications of the latest diagnostic, prognostic, and treatment data pertaining to patients infected with hepatitis C virus. In this edition of Stay Tuned Hepatitis, Nezam H. Afdhal, MD, FRCPI, provides insight into the clinical utility of new prognostic and diagnostic tools for hepatitis C; Steven Flamm, MD, reviews strategies for managing mild liver disease in the setting of HCV in 2010; and Fred Poordad, MD, highlights the likely impact of new HCV therapies on current practices in the clinic. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3540033 Thu, 06 May 2010 17:00:38 +0100 3540033 http://www.medworm.com/index.php?rid=3484562&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F1190.aspx Capsule Summary - Efficacy similar among arms receiving once- or twice-daily BI 201335, but jaundice higher in twice-daily arm. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484562 Mon, 19 Apr 2010 14:37:18 +0100 3484562 http://www.medworm.com/index.php?rid=3484563&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F54.aspx Capsule Summary - Most patients received individualized peginterferon/ribavirin treatment duration based on virologic responses; extended treatment associated with increased SVR rates in late responders. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484563 Mon, 19 Apr 2010 12:42:26 +0100 3484563 http://www.medworm.com/index.php?rid=3484565&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F53.aspx Capsule Summary - Genotype 1 HCV significantly associated with insulin resistance; SVR associated with significant reductions in IR only in genotype 1 patients (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484565 Mon, 19 Apr 2010 12:00:00 +0100 3484565 http://www.medworm.com/index.php?rid=3484564&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F56.aspx Capsule Summary - Two-thirds of treatment-naive genotype 1 HCV patients receiving telaprevir plus peginterferon/ribavirin attained undetectable HCV RNA at Week 4 and were assigned to 24 weeks of therapy; SVR observed in nearly all of these patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484564 Mon, 19 Apr 2010 12:00:00 +0100 3484564 http://www.medworm.com/index.php?rid=3484566&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FOther%2520Topics%2FCapsules%2F1185.aspx Capsule Summary - Eltrombopag associated with 53% absolute reduction in need for transfusions, but early study termination due to development of thrombotic events in 4% of patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484566 Mon, 19 Apr 2010 11:51:50 +0100 3484566 http://www.medworm.com/index.php?rid=3484567&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F1189.aspx Capsule Summary - 10-mg and 60-mg doses of first-in-class selective inhibitor of HCV-NS5A demonstrated potent activity in treatment-naive genotype 1 HCV–infected patients and associated with low rate of adverse events. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3484567 Mon, 19 Apr 2010 11:32:14 +0100 3484567 http://www.medworm.com/index.php?rid=3481677&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F1188.aspx Capsule Summary - More patients treated with nitazoxanide plus peginterferon/ribavirin achieved virologic response compared patients receiving standard of care, but differences not statistically significant. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3481677 Sun, 18 Apr 2010 16:01:54 +0100 3481677 http://www.medworm.com/index.php?rid=3481678&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F58.aspx Capsule Summary - Safety of controlled-release recombinant interferon alfa-2b/ribavirin comparable with standard peginterferon alfa-2b arm/ribavirin therapy. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3481678 Sun, 18 Apr 2010 15:19:22 +0100 3481678 http://www.medworm.com/index.php?rid=3481679&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F1187.aspx Capsule Summary - Although IL28B genotype is associated with responses to HCV treatment, hepatic levels of previously identified interferon-stimulated genes have greatest predictive value. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3481679 Sun, 18 Apr 2010 12:00:00 +0100 3481679 http://www.medworm.com/index.php?rid=3480476&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F4.aspx Capsule Summary - Safety profile of pegIFN/RBV/telaprevir triple-drug regimen in previous nonresponders to pegIFN/RBV similar to other phase II studies. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3480476 Sat, 17 Apr 2010 10:38:54 +0100 3480476 http://www.medworm.com/index.php?rid=3480477&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F38.aspx Capsule Summary - In patients with genotype 1 HCV, ritonavir boosting of low-dose danoprevir associated with high rates of undetectable HCV RNA compared with historical data with unboosted higher-dose danoprevir. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3480477 Sat, 17 Apr 2010 09:36:19 +0100 3480477 http://www.medworm.com/index.php?rid=3478380&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F2016.aspx Capsule Summary - In addition to durable response, no serious adverse events or laboratory abnormalities related to boceprevir treatment were found during the follow-up period. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3478380 Fri, 16 Apr 2010 13:54:43 +0100 3478380 http://www.medworm.com/index.php?rid=3478381&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference%2520Coverage%2FVienna%25202010%2FTracks%2FHCV%2FCapsules%2F31.aspx Capsule Summary - Novel HCV polymerase inhibitor VX-222 well tolerated and associated with HCV RNA reductions within 1 day in genotype 1 HCV patients. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3478381 Fri, 16 Apr 2010 10:31:54 +0100 3478381 http://www.medworm.com/index.php?rid=3438820&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment%2520Updates%2FStay%2520Tuned%25201%2FVolume%25201%2520Edition%25201%2FResources%2FGe_Nature_2009_CS.aspx Capsule Summary - In this genomewide association study, a genetic polymorphism near IL28B, which encodes for interferon lambda-3, was found to strongly correlate with response to peginterferon/ribavirin in individuals infected with genotype 1 HCV. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3438820 Fri, 02 Apr 2010 00:00:00 +0100 3438820 http://www.medworm.com/index.php?rid=3137090&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FConference+Coverage%2FAASLD+2009%2FTracks%2FHCV+Treatment%2FHCV_Treatment.aspx Learning Module - In this Expert Analysis, Michael P. Manns, MD; David R. Nelson, MD; and Tram T. Tran, MD, provide an in-depth review of the most important new data presented at the 2009 AASLD meeting on the management of patients with chronic HCV infection. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137090 Wed, 30 Dec 2009 12:00:00 +0100 3137090 http://www.medworm.com/index.php?rid=3137091&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+New+Directions%2FInteractive+Virtual+Presentation%2FIVP.aspx Resource - This program provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with chronic hepatitis C, helping participants navigate data from recent and ongoing clinical trials of STAT-C agents and understand their potential impact on HCV management including the prospects for reduced durations and increased efficacy of treatment in both treatment-naive and treatment-experienced patient populations. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137091 Fri, 18 Dec 2009 12:00:00 +0100 3137091 http://www.medworm.com/index.php?rid=3137092&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+Lessons%2FInteractive+Virtual+Presentation%2FHCV_Lessons.aspx Resource - Brian L. Pearlman, MD, FACP, reviews key considerations and supporting clinical data pertinent to the management of HCV nonresponders using currently available regimens. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137092 Fri, 18 Dec 2009 09:16:11 +0100 3137092 http://www.medworm.com/index.php?rid=3422403&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+Lessons%2FInteractive+Virtual+Presentation%2FLessons_Learned_Slides.aspx CCO Slideset - Brian L. Pearlman, MD, FACP, discusses management strategies for patients who have failed HCV treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3422403 Mon, 14 Dec 2009 11:23:33 +0100 3422403 http://www.medworm.com/index.php?rid=3137093&cid=s_33083_20_f&fid=33083&url=http%3A%2F%2Fwww.clinicaloptions.com%2FHepatitis%2FTreatment+Updates%2FHCV+Lessons%2FInteractive+Virtual+Presentation%2FLessons_Learned_Slides.aspx CCO Slideset - Brian L. Pearlman, MD, FACP, discusses management strategies for patients who have failed HCV treatment. (Source: Clinical Care Options Hepatitis - HCV) Clinical Care Options Hepatitis - HCV journals http://www.medworm.com/rss/comments.php?id=3137093 Mon, 14 Dec 2009 11:23:33 +0100 3137093